Mapillar Dahn: Advancing Stem Cell-Derived Red Blood Cells
Mapillar Dahn, Founder and Executive Director of MTS Sickle Cell Foundation INC, shared a post on LinkedIn:
“A step forward in the future of blood transfusions.
Safi Biotherapeutics Inc has announced a 4.7 dollars million funding extension to advance its manufactured, stem-cell-derived human red blood cells toward a first clinical trial planned for 2027.
For our sickle cell community, research like this is worth watching. We know how much families depend on access to blood, and why progress in transfusion medicine matters.
The initial clinical focus is acute blood loss, rather than sickle cell disease. These cells remain investigational, with clinical studies still needed to evaluate their safety and effectiveness.
We’re encouraged by this investment and look forward to following the science. In the meantime, blood donors remain essential. ”
Stay updated with Hemostasis Today.
-
Nov 6, 2026, 10:29Luisa Weiss: How Platelets Drive Inflammation in Aortic Valve Disease
-
Nov 6, 2026, 10:18Dave Cartland: A Rare Case of Portal Vein Thrombosis After Moderna Vaccination
-
Nov 6, 2026, 10:10Iván Camilo Triana Avellaneda: Uncovering Distinct Clinical Phenotypes of DVT
-
Nov 6, 2026, 10:06Rafael Zubirán: Lp(a) – The Missing Link Between Inflammation and Thrombosis
-
Nov 6, 2026, 09:59Syeda Jazilah Faisal: Upstream Heparin in STEMI – Improving Coronary Reperfusion Before PCI
-
Nov 6, 2026, 09:51N. Mariana S. Vasquez: Understanding the 3 Main Types of Leg Ulcers
-
Nov 6, 2026, 08:22How Bleeding Disorders Affect Social Life and Well-Being? – EHC
-
Nov 6, 2026, 08:13Jared Rice: Why Neonatal Coagulation Cannot Be Interpreted Like Adult Coagulation
-
Nov 6, 2026, 08:07Matthew Smeds: Endovascular Salvage of Acute IVC Thrombosis After Liver Transplantation